Chromatin remodeling controls Kaposi's sarcoma-associated herpesvirus reactivation from latency
Open Access
- 13 September 2018
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 14 (9) , e1007267
Abstract
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiologic agent of three human malignancies, the endothelial cell cancer Kaposi’s sarcoma, and two B cell cancers, Primary Effusion Lymphoma and multicentric Castleman’s disease. KSHV has latent and lytic phases of the viral life cycle, and while both contribute to viral pathogenesis, lytic proteins contribute to KSHV-mediated oncogenesis. Reactivation from latency is driven by the KSHV lytic gene transactivator RTA, and RTA transcription is controlled by epigenetic modifications. To identify host chromatin-modifying proteins that are involved in the latent to lytic transition, we screened a panel of inhibitors that target epigenetic regulatory proteins for their ability to stimulate KSHV reactivation. We found several novel regulators of viral reactivation: an inhibitor of Bmi1, PTC-209, two additional histone deacetylase inhibitors, Romidepsin and Panobinostat, and the bromodomain inhibitor (+)-JQ1. All of these compounds stimulate lytic gene expression, viral genome replication, and release of infectious virions. Treatment with Romidepsin, Panobinostat, and PTC-209 induces histone modifications at the RTA promoter, and results in nucleosome depletion at this locus. Finally, silencing Bmi1 induces KSHV reactivation, indicating that Bmi1, a member of the Polycomb repressive complex 1, is critical for maintaining KSHV latency. Kaposi’s sarcoma-associated herpesvirus (KSHV) is the causative agent of three human malignancies. KSHV establishes latent infection but can be reactivated from latency to the lytic phase of the viral life cycle to propagate. KSHV reactivation from latency is controlled by epigenetic changes at the promoter of the lytic gene transactivator, RTA. Here a novel inhibitor of a member of Polycomb repressive complex 1, Bmi1, stimulates KSHV reactivation from latency by altering histone modifications and nucleosome density at the RTA promoter. We also identify three additional inhibitors of histone deacetylases and bromodomain-containing proteins that induce KSHV reactivation from latency.Keywords
Funding Information
- American Cancer Society (131996-PF-18-046-01-MPC)
- National Institutes of Health (T32 CA009156)
- National Institutes of Health (CA163217)
- National Institutes of Health (DE023946)
- National Institutes of Health (CA096500)
- National Institutes of Health (CA019014)
- National Institutes of Health (CA228172)
This publication has 55 references indexed in Scilit:
- Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferationProceedings of the National Academy of Sciences, 2012
- CBX4-mediated SUMO modification regulates BMI1 recruitment at sites of DNA damageNucleic Acids Research, 2012
- RYBP-PRC1 Complexes Mediate H2A Ubiquitylation at Polycomb Target Sites Independently of PRC2 and H3K27me3Cell, 2012
- Molecular and Clinical Assessment in the Treatment of AIDS Kaposi Sarcoma with Valproic AcidClinical Infectious Diseases, 2009
- Isolation of active regulatory elements from eukaryotic chromatin using FAIRE (Formaldehyde Assisted Isolation of Regulatory Elements)Methods, 2009
- Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumorsNature Medicine, 2008
- Reactivation of Kaposi's sarcoma-associated herpesvirus from latency requires MEK/ERK, JNK and p38 multiple mitogen-activated protein kinase pathwaysVirology, 2008
- Reactivation of Kaposi's sarcoma‐associated herpesvirus by natural products from Kaposi's sarcoma endemic regionsInternational Journal of Cancer, 2006
- Role of Bmi-1 and Ring1A in H2A Ubiquitylation and Hox Gene SilencingMolecular Cell, 2005
- Role of histone H2A ubiquitination in Polycomb silencingNature, 2004